IP Library › Granted Patent US 12,303,546
Granted Patent B2
US 12,303,546 · App. 17/657,885 · Granted May 20, 2025

Antimicrobial compositions and methods of use thereof

Inventors: Vincent C. Bond (Stone Mountain, GA); Michael Powell (Douglasville, GA); Ming Bo Huang (Atlanta, GA); Syed Ali (New Iberia, LA); Martin N. Shelton (Mountlake Terrace, WA)
Assignee: MOREHOUSE SCHOOL OF MEDICINE
A61K38/162A61K38/08A61K45/06A61K47/60C07K7/06C12N7/00C12N2740/16032Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,303,546
App. No.
17/657,885
Granted
May 20, 2025
Kind
B2
Abstract

The present application discloses a method for treating microbial infection using an antimicrobial composition comprises antimicrobial peptide which contains at least one VGFPV motif.

Claims (5)

1. A pharmaceutical composition for treating a gram positive or gram negative bacterial infection, comprising: (1) an antimicrobial peptide comprising an antimicrobial domain comprising the amino acid sequence of SEQ ID NO: 3 bound at the N- or C-terminus to a cell penetrating peptide (CPP) domain; and (2) a pharmaceutically acceptable carrier; wherein the CPP is one selected from the group consisting of HIV TAT49-.s7 peptide, HIV TAT 48-60 peptide, low molecular weight protamine (LMWP) peptide; Pep-1; Antp43-58 peptide, MPG (HIV Gp41-SV40 NLS), SAP, MPG R9, MAP, K-FGF, Penetratin, Buforin II, Transportan, Ku70, Prion, pVEC, Pep-1-K, Pep-7, HN-1, TP10, and CP26.

2. The composition of claim 1 , wherein the antimicrobial peptide further comprises a second antimicrobial domain, wherein said second antimicrobial domain is different from said first antimicrobial domain.

3. The composition of claim 1 , wherein the antimicrobial peptide further comprises a targeting domain.

4. The composition of claim 1 , wherein the antimicrobial peptide comprises the antimicrobial domain at the N-terminus.

5. The composition of claim 1 , wherein the antimicrobial peptide comprises the antimicrobial domain at the C-terminus.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2022
From: BOND, VINCENT C.; POWELL, MICHAEL D.; HUANG, MING BO; ALI, SYED; SHEL TON, MARTIN NEVILLE
To: MOREHOUSE SCHOOL OF MEDICINE
Reel/Frame 061835/0148 →
Continuity (6)
Continuation 16947808 · Aug 18, 2020
Continuation 16241316 · Jan 7, 2019
Continuation 15397359 · Jan 3, 2017
Continuation 14156119 · Jan 15, 2014
Continuation 13267977 · Oct 7, 2011
Related Publication 20220249600A1 · Aug 11, 2022
References Cited (38)
US 8431530B2 · Bond et al. · 2013 [cited by applicant]
US 8476237B2 · Bond et al. · 2013 [cited by applicant]
US 8551943B2 · Bond et al. · 2013 [cited by applicant]
US 8563506B2 · Bond · 2013 [cited by examiner]
US 8669226B2 · Bond · 2014 [cited by examiner]
US 9556224B2 · Bond · 2017 [cited by examiner]
US 10206974B2 · Bond · 2019 [cited by examiner]
US 10800817B2 · Bond · 2020 [cited by examiner]
US 11180534B1 · Bond · 2021 [cited by examiner]
US 11304974B2 · Lostao Camón · 2022 [cited by examiner]
US 11304991B2 · Bond · 2022 [cited by examiner]
US 11414462B1 · Bond · 2022 [cited by examiner]
US 20060140911A1 · Sharp et al. · 2006 [cited by applicant]
US 20070055049A1 · Grey et al. · 2007 [cited by applicant]
US 20080057036A1 · Yacoby et al. · 2008 [cited by applicant]
US 20100061932A1 · Brock et al. · 2010 [cited by applicant]
US 20100317566A1 · Bond et al. · 2010 [cited by applicant]
US 20100322929A1 · Zurawski et al. · 2010 [cited by applicant]
US 20110020290A1 · Soothill et al. · 2011 [cited by applicant]
US 20110046008A1 · Love et al. · 2011 [cited by applicant]
US 20130018002A1 · Bond et al. · 2013 [cited by applicant]
US 20130018003A1 · Bond et al. · 2013 [cited by applicant]
US 20130123202A1 · Bond et al. · 2013 [cited by applicant]
US 20140155319A1 · Bond et al. · 2014 [cited by applicant]
US 20220249600A1 · Bond · 2022 [cited by examiner]
Morris, et al., “A Peptice Carrier for the Delivery of Biologically Active Proteins into Mammalian Cells: Application to the Delivery of Antibodies and Therapeutic Proteins”, Nature Biotechnology, vol. 19, pp. 1173-1176… [cited by applicant]
Joliot, et al., “Transduction peptides: from technology to physiology”, Nature Cell Biology, vol. 6, No. 3, pp. 189-196. [cited by applicant]
Heitz, et al., “Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics”, British Journal of Pharmacology, vol. 157, pp. 196-206 (2009). [cited by applicant]
Yacoby, et al., “Targeting Antibacterial Agents by Using Drug-Carrying Filamentous Bacteriophages”, Antimicrobial Agents and Chemotherapy (AAC), vol. 50, No. 6, pp. 2087-2097 (2006). [cited by applicant]
Yacoby, et al. “Targeted Drug-Carrying Bacteriphages as Antibacterial Nanomedicines”, Antimicrobial Agents and Chemotherapy (AAC), vol. 51, No. 6, pp. 2156-2163 (2007). [cited by applicant]
Proft, “Sortase-mediated protein ligation. an emerging biotechnology tool for protein modification and immobilisation”, Biotechnol Lett, vol. 32, pp. 1-10 (2010). [cited by applicant]
Ali, S.A., et al., “Genetic Characterization of HIV Type 1 Nef-Induced Vesicle Secretion”, AIDS Research and Human Retroviruses, vol. 29, No. 2, pp. 173-192 (2010). [cited by applicant]
http://en.wikipedia.org/wiki/Polymyxin, last updated Oct. 26, 2014. [cited by applicant]
File History of U.S. Appl. No. 16/241,316, filed Jan. 7, 2019. [cited by applicant]
File History of U.S. Appl. No. 15/397,359, filed Jan. 3, 2017. [cited by applicant]
File History of U.S. Appl. No. 14/156,119, filed Jan. 15, 2014. [cited by applicant]
File History of U.S. Appl. No. 13/267,977, filed Oct. 7, 2011. [cited by applicant]
File History of U.S. Appl. No. 116/947,808, filed Aug. 18, 2020. [cited by applicant]